Second partner I would like to present here is Hoffmann La Roche- short -Roche. In the same conference call early 2009 when Calhoun talked about his partners, he described the proprietary enzyme supplier as a "unnamed major US pharma partner, which we dont want to disclose for competitive reasons"- just to make things easy.(LOL)

Roche is a top notch biotech, which is illustrated by their bid for Illumina (on top of owning antibody giant Genentech)- that bid is all about personalized targeted gene therapy for oncology patients- exactly what Burzynski -link here is doing right now and to me the absolute FUTURE for cancer treatment. But which the FDA apparently doesnt like. (Deal didnt get established, but proves nonetheless the quality of the organisation) A perfect partner for Cytori therefore- visionaries and capable in handling other things than an "off-the-shelf" product.

Actually Astellas is of course a little more than just a candidate, since on December 7, 2010 they took an equity participation in Cytori, with the first right to negotiate a deal on liver regeneration. Cytori explained this in a note as follows:

Such a partnership would likely revolve around what we refer to as our Version 2.0 Celution® and cell therapy technology (and what Astellas calls ‘regenerative drug technology’), which is the combination of cells with pharmaceutical agents to enhance certain properties or mechanisms of the cells. This could be accomplished by incubating the cells and pharma agent outside the body or injecting the cells in combination with a systemic delivery of the drug. In addition to their negotiating right, Astellas received the right to a non-voting seat on Cytori’s board of directors and a position on our scientific advisory board.

Some people close to the matter could report that this "regenerative DRUG technology" would be related to of course ADRCs AND the drug "PROGRAF". It is well-known that Prograf looses certain patent protection in the US in 2011, but its worth having a look on what it does.

Wednesday, 08 February 2012 18:00

Cytori´s Platform Applications


Cytori´s immensely large technology platform

The versatility of ADRC´s in general provides a gigantic opportunity for Cytori as a first mover in this space, to collect the low hanging fruit and establish themselves before others do so, whilst being protected by an impressive IP portfolio in the mean time.

As a general rule of thumb, what has crystalized out to a large degree by now is, that because of the abundance of EPCs, (endothelial progenitors) and smooth muscle progenitors,

Published in Cytori- Its Technology

Copyright Information

Copyright Fas Kuiters © 2016 All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.



Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites